Capstone Investment Advisors
VIR icon

Capstone Investment Advisors’s Vir Biotechnology VIR Stock Holding History

Capstone Investment Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-13,306
Closed -$118K – 2221
2024
Q2 		$118K Buy
+13,306
New +$128K ﹤0.01% 1863

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Capstone Investment Advisors's VIR Position: Q3 2024 in Review

Capstone Investment Advisors sold out of Vir Biotechnology (VIR) in Q3 2024, closing a stake of 13,306 shares — an estimated $118K sold.

Capstone Investment Advisors first reported a position in VIR in Q2 2024 and held it in 1 quarter. The position peaked at $118K in Q2 2024. 197 funds tracked by Wall St. Rank hold VIR as of Q3 2024.

  • Capstone Investment Advisors reported no remaining Vir Biotechnology position as of Q3 2024 after selling out during the quarter.
  • Capstone Investment Advisors sold 13,306 Vir Biotechnology shares in Q3 2024, an estimated $118K.
  • Capstone Investment Advisors first reported a position in Vir Biotechnology in Q2 2024 and held it in 1 quarter.
  • Capstone Investment Advisors's Vir Biotechnology position peaked at $118K in Q2 2024.
  • 197 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2024.

Based on Capstone Investment Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.